The **cumulative burden of polypharmacy in aging multiple sclerosis (MS) populations** refers to the combined impact of taking many medications over time on older adults living with MS. Polypharmacy means regularly using multiple medications, often five or more, which is…
Geriatric co-management has the potential to significantly optimize care for older adults living with multiple sclerosis (MS) by addressing the complex interplay of aging-related changes and the unique challenges posed by MS. As people with MS age, their healthcare needs…
Frailty and late-life multiple sclerosis (MS) intersect in complex ways that significantly impact how older adults with MS tolerate treatments and manage their disease. Frailty is a clinical syndrome characterized by decreased physiological reserves and increased vulnerability to stressors, leading…
Transitioning from pediatric to adult healthcare can be a challenging process for young adults, especially those living with complex conditions like multiple sclerosis (MS). MS is a chronic neurological disorder that affects the central nervous system, leading to symptoms such…
The transition from pediatric to adult care in multiple sclerosis (MS) is a critical period that can significantly influence health outcomes for young people living with this chronic neurological disease. This transition involves shifting from a pediatric healthcare environment, which…
Explainable AI (XAI) has the potential to significantly improve clinician trust in multiple sclerosis (MS) risk models by making the AI’s decision-making process transparent, understandable, and clinically relevant. MS risk models, which predict disease progression or treatment outcomes, often rely…
Artificial intelligence (AI) is increasingly being integrated into medical decision support tools for multiple sclerosis (MS), promising to enhance diagnosis, monitor disease progression, and personalize treatment plans. However, deploying AI-driven MS decision support tools safely and effectively requires a comprehensive…
Community-based research holds significant promise in reducing disparities in multiple sclerosis (MS) clinical trials by fostering inclusivity, cultural relevance, and trust among underrepresented populations. These disparities often arise because traditional MS trials tend to enroll participants who do not fully…
Cultural beliefs profoundly shape how people understand, respond to, and manage multiple sclerosis (MS), influencing both diagnosis and treatment uptake in diverse ways. These beliefs affect perceptions of the disease’s nature, its causes, and the appropriateness of medical interventions, which…
Return-of-results policies, which involve giving individuals or families access to genetic or health-related findings from research or clinical testing, have the potential to improve prevention efforts in high-risk families by enabling earlier awareness and intervention. When families learn about genetic…